Immunogenicity according to reactogenicity of Covid-19 vaccines
- Conditions
- Vaccination against SARS-CoV-2U11.9
- Registration Number
- DRKS00025316
- Lead Sponsor
- niversitätsklinikum Regensburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
o minimum age 18 years
o two doses of BNT 162b2 at intervals of 3-6 weeks o 2nd dose 4-10 weeks before enrolment
o informed consent
Exclusion Criteria
o no informed consent
o no willingness to complete the survey
o no history of covid-19
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SARS-CoV-2 antibody level and T-cell response measured with ELISpot 4-10 weeks after 2nd vaccination with BNT162b2.<br><br><br><br>
- Secondary Outcome Measures
Name Time Method survey results (demographic information, vaccine reaction information etc.)